Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib in metastatic uveal melanoma
2021-002248-60Phase 2Active
- Sponsor
- Institut Curie
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in intraocular melanoma, sponsored by Institut Curie. Primary endpoint: Progression-free survival rate at 27 weeks. Started Dec 2021; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2021-002248-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002248-60.